Celldex Ends Eczema Drug Development After Phase 2 Results
Celldex will stop developing barzolvolimab for moderate to severe eczema after a Phase 2 study failed to meet the company’s key measures for continued development, despite showing some benefit, the biopharmaceutical company said.
November 20, 2026, 02:31 AM 1,526 0
The improvements seen with the antibody did not clear Celldex’s internal hurdle rate. The company said the results suggested mast cells contribute to eczema but are not its primary driver.
Barzolvolimab showed a favorable safety and tolerability profile, consistent with previously reported studies, Celldex said.
Comments (0)
No comments yet. Be the first!